It's pretty common to see a biotech tank on any given day, so when three companies dropped substantially the other day, it wasn't that surprising. Unless you're an investor in the companies, of course.
Seattle Genetics (NASDAQ:SGEN), which sells cancer drug Adcetris, dropped because revenue was only up 19%. While that wasn't exactly the growth investors were hoping for, Seattle Genetics still has a substantial pipeline worth owning.
Pharmacyclics (NASDAQ:PCYC) was another earnings "loser." During the first full quarter on the market, demand for its cancer drug, Imbruvica, came in at a little over $50 million. Despite getting a second approval in mid February for CLL, which is a larger market than mantle cell lymphoma that it was first approved for, Pharmacyclics guided for sales of just $295 million for the year.
Finally, Endocyte (NASDAQ:ECYT) was the loser of the group after announcing that its trial testing vintafolide in ovarian-cancer patients was stopped early for futility. Based on data to date, the data monitoring committee believes the trial won't be able to show that vintafolide increases in progression-free survival if Endocyte let it go to completion.
In the video below, senior biotech specialist Brian Orelli and health care analyst David Williamson discuss the drops and which companies might be bad-news buys.
"I'd rather buy a good company at a fair price than buy a fair company at a good price."
And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock... and join Buffett in his quest for a veritable landslide of profits!
Brian Orelli and David Williamson have no positions in any stocks mentioned. The Motley Fool recommends Seattle Genetics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.